Antagonist of A3 Adenosine Receptor Fluorescent Probes for the Study of Diseases that Involve A3 Signaling

This molecular probe may serve as a companion tool to identify and stratify patient populations based on the prevalence of the target A3adenosine receptors.

Patent Abstract:

This molecular probe may serve as a companion tool to identify and stratify patient populations based on the prevalence of the target A3adenosine receptors. Small molecule drugs, A3AR-selective agonists, are currently in advanced clinical trials for the treatment of hepatocellular carcinoma, autoimmune inflammatory diseases, such as rheumatoid arthritis, psoriasis, and dry eye disease, and other conditions.

Benefits

Avoids the use of radioisotopes in this part of the R&D process.

applications

Inventors:

Kenneth Jacobson

Patent Number:

13/748,826 (Note: a separate license may be requir

Internal Laboratory Ref #:

E-073-2012/0

National Institute of Diabetes and Digestive and Kidney Diseases

Agency

Dept. of Health and Human Services